What type of study is this?

This is a Human Clinical Trial study (also classified as: RCT).

What question did this study set out to answer?

This analysis aims to evaluate the quality and timing of patient-reported outcomes in lymphoma randomized controlled trials.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Analysis of 83 RCTs reveals gaps in patient-reported outcome reporting quality and timing for lymphoma treatments.

This analysis aims to evaluate the quality and timing of patient-reported outcomes in lymphoma randomized controlled trials.
Analyzed 83 RCTs with PRO endpoints in lymphoma and multiple myeloma published between 2015 and 2025.
Examined data using the CONSORT-PRO checklist to assess reporting quality.
Conducted univariable and multivariable linear regression analyses on CONSORT-PRO scores.
The median CONSORT-PRO score was 9.5, indicating moderate quality of reporting.
55% of RCTs showed a significant difference in PRO scales between treatment arms.
The median time from primary RCT publication to PRO results publication was 1.8 years.

Shah et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark